Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 14/20 | 0.45 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | PEPD | P12955 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.39 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | CTRC | Q99895 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7316962 | 0.85 | CMA1 (0.51) | KLK5CMA1ELANEPEPDCTSL | |
| SCHEMBL8352620 | 0.85 | CMA1 (0.51) | KLK5CMA1ELANEPEPDCTSL | |
| SCHEMBL8168154 | 0.85 | CMA1 (0.51) | KLK5CMA1ELANEPEPDCTSL | |
| SCHEMBL4369534 | 0.84 | PEPD (0.46) | KLK5CMA1ELANEPEPDXPNPEP1 | |
| SCHEMBL8046113 | 0.84 | KLK5 (0.51) | KLK5CMA1ELANEPEPDXPNPEP1 | |
| SCHEMBL14202917 | 0.84 | KLK5 (0.51) | KLK5CMA1ELANEPEPDXPNPEP1 | |
| SCHEMBL4372740 | 0.81 | PEPD (0.50) | CMA1ELANEPEPDXPNPEP1ACE | |
| SCHEMBL7311829 | 0.80 | KLK5 (0.53) | KLK5CMA1ELANEPEPDCTSL | |
| SCHEMBL17348390 | 0.80 | KLK5 (0.53) | KLK5CMA1ELANEPEPDCTSL | |
| SCHEMBL14235323 | 0.80 | KLK5 (0.53) | KLK5CMA1ELANEPEPDCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7626023-B2 | Compounds for treating tumors | WYETH (US) | 2009-12-01 | — | — | US | disclosed |
| US-20080221181-A1 | COMPOUNDS FOR TREATING TUMORS | WYETH HOLDINGS CORPORATION (US) | 2008-09-11 | — | — | US | disclosed |
| US-7390910-B2 | Compounds for treating tumors | WYETH (US) | 2008-06-24 | — | — | US | disclosed |
| WO-2005016958-A2 | COMPOUNDS FOR TREATING TUMORS | WYETH HOLDINGS CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
| US-20050037977-A1 | Compounds for treating tumors | WYETH HOLDINGS CORPORATION (US) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221181-A1 | COMPOUNDS FOR TREATING TUMORS | RB1, MRPL9, BCOR | KLK5 2724/4885CMA1 2238/4885ELANE 3419/4885 |
| US-20050037977-A1 | Compounds for treating tumors | RB1, MRPL9, BCOR | KLK5 2724/4885CMA1 2238/4885ELANE 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.